Zydelig Evropska unija - slovenščina - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Libtayo Evropska unija - slovenščina - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Prograf 0,5 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prograf 0,5 mg trde kapsule

astellas pharma d.o.o. - takrolimus - kapsula, trda - takrolimus 0,5 mg / 1 kapsula - takrolimus

Prograf 1 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prograf 1 mg trde kapsule

astellas pharma d.o.o. - takrolimus - kapsula, trda - takrolimus 1 mg / 1 kapsula - takrolimus

Prograf 5 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prograf 5 mg trde kapsule

astellas pharma d.o.o. - takrolimus - kapsula, trda - takrolimus 5 mg / 1 kapsula - takrolimus

SPORANOX 100 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sporanox 100 mg trde kapsule

johnson & johnson d.o.o. - itrakonazol - kapsula, trda - itrakonazol 100 mg / 1 kapsula - itrakonazol

Modigraf Evropska unija - slovenščina - EMA (European Medicines Agency)

modigraf

astellas pharma europe b.v. - takrolimus - zavrnitev presadka - imunosupresivi - preprečevanje zavrnitve presadka pri prejemnikih alogenskega presadka pri odraslih in pediatričnih, ledvičnih, jetrnih ali srčnih. zdravljenje allograft zavrnitev odporne na zdravljenje z drugimi imunosupresivnimi zdravili pri odraslih in pediatričnih bolnikih.

Tavlesse Evropska unija - slovenščina - EMA (European Medicines Agency)

tavlesse

instituto grifols s.a. - fostamatinib disodium - trombocitopenija - drugi sistemski hemostatics - tavlesse je indiciran za zdravljenje kronične imunska trombocitopenija (itp) pri odraslih bolnikih, ki so utrjene za druge oblike zdravljenja.